JPWO2020188573A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020188573A5 JPWO2020188573A5 JP2021556492A JP2021556492A JPWO2020188573A5 JP WO2020188573 A5 JPWO2020188573 A5 JP WO2020188573A5 JP 2021556492 A JP2021556492 A JP 2021556492A JP 2021556492 A JP2021556492 A JP 2021556492A JP WO2020188573 A5 JPWO2020188573 A5 JP WO2020188573A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- matched
- mismatched
- cells
- depleted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (13)
- 血液疾患の治療を必要とする対象において血液疾患を治療するためのキットであって、
(a)オビヌツズマブと、
(b)少なくとも1種の免疫抑制剤と、
(c)栄養素、血清、IL-15及び1.0mM~10mMのニコチンアミドを用いたエクスビボ培養下で増殖した、HLA半合致又はHLA不適合の増殖CD3枯渇NK細胞画分と、
(d)IL-2と
を含むキット。 - 前記免疫抑制剤は、化学療法免疫抑制剤である、請求項1に記載のキット。
- 血液疾患の治療を必要とする対象において血液疾患を治療するためのキットであって、
(a)オビヌツズマブと、
(b)栄養素、血清、IL-15及び1.0mM~10mMのニコチンアミドを用いたエクスビボ培養下で増殖した、HLA半合致又はHLA不適合の増殖CD3枯渇NK細胞画分と、
(c)IL-2と
を含み、前記対象は、放射線治療を受けた免疫抑制された対象である、キット。 - 前記血液疾患は、血液系腫瘍、任意でCD20陽性リンパ系腫瘍である、請求項1~3のいずれか一項に記載のキット。
- 前記血液疾患は、多発性骨髄腫である、請求項1~3のいずれか一項に記載のキット。
- 前記血液疾患は、非ホジキンリンパ腫(NHL)、任意でCD20陽性B細胞NHLである、請求項1~3のいずれか一項に記載のキット。
- 前記増殖CD3枯渇HLA半合致又は不適合NK細胞画分は、連続日に投与するための2つの用量で提供される、請求項1~6のいずれか一項に記載のキット。
- 前記NK細胞画分は、1×107個/kg~5×108個/kgの増殖CD3枯渇HLA半合致又はHLA不適合NK細胞を含む、請求項1~6のいずれか一項に記載のキット。
- (a)前記NK細胞画分の前記第1の用量と前記第2の用量は、各々、1×107個/kgの増殖CD3枯渇HLA半合致又は不適合NK細胞を含み、増殖CD3枯渇HLA半合致又は不適合NK細胞の総用量は、2×107個/kgである、又は
(b)前記NK細胞画分の前記第1の用量と前記第2の用量は、各々、5×107個/kgの増殖CD3枯渇HLA半合致又は不適合NK細胞を含み、増殖CD3枯渇HLA半合致又は不適合NK細胞の総用量は、1×108個/kgである、又は
(c)前記NK細胞画分の前記第1の用量と前記第2の用量は、各々、1×108個/kgの増殖CD3枯渇HLA半合致又は不適合NK細胞を含み、増殖CD3枯渇HLA半合致又は不適合NK細胞の総用量は、2×108個/kgである、請求項7に記載のキット。 - 前記少なくとも1種の免疫抑制剤は、シクロホスファミド及び/又はフルダラビンを含み、任意で、シクロホスファミド(40mg/kg)とフルダラビン(25mg/m 2 )との両方を含む、請求項1に記載のキット。
- 前記IL-2は、前記増殖CD3枯渇NK細胞の輸注後の3日目、4日目および5日目に投与するための、6×10 6 単位からなる用量を3つ含む、請求項1に記載のキット。
- 前記増殖CD3枯渇HLA半合致又はHLA不適合のNK細胞画分は、以下のパラメータによって特徴付けられる、請求項1~11のいずれか一項に記載のキット。
(a)CD56+/CD3-細胞が少なくとも70%、
(b)生存率が少なくとも70%、
(c)注入の際の、患者当たりのCD3+細胞数が5.0×105個/体重1Kg未満、
(d)注入の際の、患者当たりの内毒素が5EU/体重1Kg以下、及び
(e)グラム陽性微生物なし。 - 前記増殖CD3枯渇HLA半合致又はHLA不適合のNK細胞画分は、フッ素化エチレンプロピレン(FEP)培養バッグで提供される、請求項1~12のいずれか一項に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962821535P | 2019-03-21 | 2019-03-21 | |
US62/821,535 | 2019-03-21 | ||
PCT/IL2020/050331 WO2020188573A1 (en) | 2019-03-21 | 2020-03-19 | Expanded nk cell fractions for transplantation in combination therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022525928A JP2022525928A (ja) | 2022-05-20 |
JPWO2020188573A5 true JPWO2020188573A5 (ja) | 2023-03-24 |
Family
ID=72519788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021556492A Pending JP2022525928A (ja) | 2019-03-21 | 2020-03-19 | 併用療法における移植に適したnk細胞画分の増殖及び増殖nk細胞画分の使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220249555A1 (ja) |
EP (1) | EP3941489A4 (ja) |
JP (1) | JP2022525928A (ja) |
CN (1) | CN113853204A (ja) |
AU (1) | AU2020243703A1 (ja) |
CA (1) | CA3133419A1 (ja) |
IL (1) | IL286482A (ja) |
SG (1) | SG11202110261QA (ja) |
WO (1) | WO2020188573A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3226076A1 (en) * | 2021-07-18 | 2023-01-26 | Tracey Lodie | Therapeutic nk cell populations |
KR20240054424A (ko) * | 2021-08-10 | 2024-04-25 | 가미다-셀 리미티드 | 항-her2 car nk 세포, 이의 생산 방법 및 용도 |
JP2024515920A (ja) * | 2022-04-08 | 2024-04-11 | フェイト セラピューティクス,インコーポレイティド | 固形腫瘍標的化骨格を有する細胞及びその使用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030082646A1 (en) * | 1998-12-29 | 2003-05-01 | The Regents Of The University Of Michigan | Antigenic targets of autoimmune sensorineural hearing loss (AISNHL) and development of tests for diagnosis and management of AISNHL |
AU2003275767A1 (en) * | 2002-11-07 | 2004-06-07 | Johnson & Johnson Research Pty Limited | A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes |
KR101368035B1 (ko) * | 2005-04-08 | 2014-02-26 | 아르고스 쎄라퓨틱스 인코포레이티드 | 수지상 세포 조성물 및 방법 |
WO2007027748A2 (en) * | 2005-08-31 | 2007-03-08 | Medimmune, Inc. | C/clp antagonists and methods of use thereof |
US8415150B2 (en) * | 2009-02-24 | 2013-04-09 | The Trustees Of The University Of Pennsylvania | Methods for treating progressive multifocal leukoencephalopathy (PML) |
EP2411507B1 (en) * | 2009-03-26 | 2019-09-25 | CellProtect Nordic Pharmaceuticals AB | Expansion of nk cells |
US20130011376A1 (en) * | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
TWI619729B (zh) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗-hla-b*27抗體及其用途 |
PE20170140A1 (es) * | 2014-07-16 | 2017-03-30 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer |
EA035098B1 (ru) * | 2014-07-31 | 2020-04-27 | Санофи | Способ лечения рецидивирующей и/или рефрактерной множественной миеломы |
RS60349B8 (sr) * | 2014-09-23 | 2022-10-31 | Hoffmann La Roche | Postupak upotrebe anti-cd79b imunokonjugata |
WO2016077734A2 (en) * | 2014-11-14 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors |
JP6797803B2 (ja) * | 2014-12-31 | 2020-12-09 | セルジーン コーポレイション | ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法 |
EP3851110A1 (en) * | 2015-05-28 | 2021-07-21 | Kite Pharma, Inc. | Methods of conditioning patients for t cell therapy |
US20200016198A1 (en) * | 2015-11-05 | 2020-01-16 | Glycostem Therapeutics B.V. | Composition for use in immunotherapy |
AU2017210031C1 (en) * | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
WO2017137085A1 (en) * | 2016-02-11 | 2017-08-17 | Sanofi Pasteur | Meningitidis vaccines comprising subtilinases |
WO2018151820A1 (en) * | 2017-02-16 | 2018-08-23 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
WO2019069184A2 (en) * | 2017-10-02 | 2019-04-11 | Gamida-Cell Ltd. | EXPANSION AND USE OF EXTENDED NK CELL FRACTIONS |
-
2020
- 2020-03-19 WO PCT/IL2020/050331 patent/WO2020188573A1/en unknown
- 2020-03-19 EP EP20772607.6A patent/EP3941489A4/en active Pending
- 2020-03-19 JP JP2021556492A patent/JP2022525928A/ja active Pending
- 2020-03-19 CA CA3133419A patent/CA3133419A1/en active Pending
- 2020-03-19 CN CN202080037287.9A patent/CN113853204A/zh active Pending
- 2020-03-19 US US17/439,971 patent/US20220249555A1/en active Pending
- 2020-03-19 AU AU2020243703A patent/AU2020243703A1/en active Pending
- 2020-03-19 SG SG11202110261QA patent/SG11202110261QA/en unknown
-
2021
- 2021-09-19 IL IL286482A patent/IL286482A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Martı́nez et al. | Immune reconstitution following allogeneic peripheral blood progenitor cell transplantation: comparison of recipients of positive CD34+ selected grafts with recipients of unmanipulated grafts | |
Soiffer et al. | CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission | |
Chang et al. | Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom? | |
JPH09510456A (ja) | 同種リンパ球による癌の免疫療法 | |
Symons et al. | Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors | |
WO2016179684A1 (en) | Method for expansion of double negative regulatory t cells | |
Statkute et al. | Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation | |
Slavin | New strategies for bone marrow transplantation | |
Martin et al. | Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute | |
McGuirk et al. | Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation | |
Cowan et al. | Haploidentical bone marrow transplantation for severe combined immunodeficiency disease using soybean agglutinin-negative, T-depleted marrow cells | |
Mokyr et al. | The development of in vitro and in vivo anti-tumor cytotoxicity in noncytotoxic, MOPC-315-tumor-bearer, spleen cells “educated” in vitro with MOPC-315 tumor cells | |
DK2717887T3 (en) | Methods for treating or preventing graft-versus-host disease | |
Ringden et al. | Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation | |
Castagna et al. | Feasibility and efficacy of CD45RA+ depleted donor lymphocytes infusion after haploidentical transplantation with post-transplantation cyclophosphamide in patients with hematological malignancies | |
Shpall | The utilization of cytokines in stem cell mobilization strategies | |
Matsuda et al. | Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors | |
JPWO2020188573A5 (ja) | ||
Devine et al. | Recent advances in allogeneic hematopoietic stem-cell transplantation | |
Taniyama et al. | Requirement of histocompatible macrophages for the induction of a secondary cytotoxic response to syngeneic tumor cells in vitro | |
Waller et al. | New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells | |
Tanaka | Recent advances in cellular therapy for malignant lymphoma | |
Aversa et al. | Hematopoietic stem cell transplantation from alternative donors for high-risk acute leukemia: the haploidentical option | |
Li et al. | Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT | |
Ringden et al. | Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age |